A HOUSE RESOLUTION TO ENCOURAGE EACH INDIVIDUAL IN SOUTH CAROLINA TO BECOME BETTER INFORMED ABOUT AND AWARE OF KIDNEY DISEASE AND APOL1-MEDIATED KIDNEY DISEASE, TO ENCOURAGE PEOPLE FROM OR WITH ANCESTRY FROM WESTERN AND CENTRAL AFRICA TO CONSIDER GENETIC TESTING FOR APOL1 GENE MUTATIONS, AND TO DECLARE TUESDAY, APRIL 29, 2025, AS "APOL1-MEDIATED KIDNEY DISEASE AWARENESS DAY" IN THE STATE OF SOUTH CAROLINA.
Impact
The bill is designed to address significant health disparities faced by African Americans regarding kidney health. By declaring April 29, 2025, as 'APOL1-Mediated Kidney Disease Awareness Day,' the resolution aims to promote genetic testing, particularly among those of West and Central African descent, who are at higher risk for genetic mutations linked to kidney disease. This initiative not only encourages personal responsibility towards health but also fosters community education about potential interventions and healthier lifestyle choices that can mitigate risks associated with kidney disease.
Summary
House Bill H4288 is a resolution aimed at raising awareness about kidney disease, particularly focusing on APOL1-mediated kidney disease. It encourages individuals in South Carolina to become better informed about the disease, highlighting the disproportionate impact on African Americans. The bill acknowledges that kidney disease affects around thirty-seven million Americans, with a significant number undergoing dialysis. The resolution recognizes the alarming statistics that show Black individuals represent a disproportionate share of kidney disease cases and stresses the need for increased awareness and education.
Contention
Notable contention arises from the financial and emotional burdens that kidney failure imposes on individuals and public health systems, particularly the Medicare program. The bill emphasizes a preemptive approach to health, advocating for genetic testing and regular health monitoring before the onset of severe symptoms. The absence of FDA-approved treatments for APOL1-mediated kidney disease signifies the need for further research and clinical trials, which may invoke discussions about funding and resource allocation for kidney health initiatives.